TLDR
- IOVA stock surged more than 40% to a new 52-week high after Q2 results beat Wall Street estimates
- Product revenue hit a record $99.3M, up ~66% year-over-year, beating consensus by $11.5M
- Amtagvi generated ~$91M in U.S. revenue, growing 40% from Q4 2025
- Gross margin reached 56%, with management expecting continued improvement ahead
- Iovance is now reviewing its full-year 2026 revenue guidance of $350M-$370M upward
Iovance Biotherapeutics stock jumped more than 40% on Thursday, hitting a new 52-week high after the company posted record Q2 2026 results that topped analyst expectations by a wide margin.
Iovance Biotherapeutics, Inc., IOVA
Product revenue came in at $99.3 million for the quarter, up from $59.9 million in Q2 2025. That beat the Street consensus by $11.5 million.
The growth was driven almost entirely by Amtagvi, its FDA-approved cell therapy for late-stage melanoma. The treatment brought in roughly $91 million in U.S. revenue, a 40% jump from Q4 2025.
Today, Iovance reported Q2 2026 financial results and corporate updates — a quarter of strong momentum across the business. Read the press release: https://t.co/ZZ7jgAPKzg | Join our live webcast at 8:30 a.m. ET today or listen to the replay: https://t.co/HQYDrJFuMM pic.twitter.com/NqnEDAvygv
— Iovance Biotherapeutics (@IovanceBio) August 6, 2026
Gross margin for the quarter hit 56%, excluding depreciation and amortization. Management said it expects that figure to keep climbing as manufacturing matures.
Net loss for the quarter was $47.3 million, down about 58% from the same period a year ago. R&D expenses also fell around 6% from the prior quarter, the fourth consecutive quarter of improving operational efficiency.
Cash and investments totaled approximately $304 million as of June 30, 2026, giving the company a solid runway.
Guidance Under Review
Interim CEO Frederick Vogt said the company is now revisiting its full-year 2026 revenue guidance of $350 million to $370 million. An update is expected during Q3.
“Based on our second-quarter performance and strong demand trends, we are reviewing our previously issued 2026 revenue guidance,” Vogt said.
That guidance review, rather than a firm raise, is what the market is reacting to. Investors appear to be pricing in a meaningful upward revision.
Unaided physician awareness for Amtagvi has nearly tripled over the prior year, supported by a new marketing campaign and an expanded sales force.
The ATC network now includes more than 95 authorized treatment centers across the U.S., Canada, and Australia. Iovance expects at least 110 active ATCs by the end of 2026, with community centers making up about one-third of that network.
Pipeline and International Expansion
Beyond the commercial business, the FDA recently granted Fast Track Designation for lifileucel in soft tissue sarcomas, including undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
The company has multiple registrational programs running across non-small cell lung cancer, sarcomas, endometrial cancer, and next-generation TIL candidates.
Internationally, Amtagvi received approval from Australia’s TGA. The UK MAA has been resubmitted and is under expedited MHRA review. A potential Switzerland approval is expected in the first half of 2027, with an EU MAA resubmission on track for the same year.
Amtagvi’s manufacturing turnaround time now sits at 31 days or less, supported by centralized scaled commercial manufacturing.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
